DOCSLIB.ORG

Narcotic Drugs Stupefiants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Narcotic Drugs Stupefiants E/INCB/1989/2/Supp.10 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 10 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1990 STATISTICS FOR 1988 ESTIMATES UPDATED AS OF31 OCTOBER 1990 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT NO 10 A STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1990 STATISTIQUES POUR 1988 EVALUATIONS A JOUR AU 31 OCTOBRE 1990 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N. o 10 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1990 ESTADIsTICAS PARA 1988 PREVISIONES ACTUALIZADAS AL 31 DE OCTUBRE DE 1990 ~..ft•.~~ ~ --;>~iJ? UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1990 The updating of Table I is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the first 11 supplements will appear in English only. Reading of these 11 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing at the end of the annual publication. The last supplement will be trilingual. La mise a jour du tableau I s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tAche des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De cette maniere, chaque supplement annule et remplace entierement le tableau publie. En vue d'accelerer la communica­ tion des supplements aux autorites competentes, les onze premiers supplements seront publies seulement en anglais. La lecture en francais et en espagnol de ces onze supplements pourra etre facilitee par la consultation des index des pays et territoires et des stupefiants a la fin de la pUblication annuelle. Le dernier supplement sera trilingue. La actualizaci6n del cuadro I se efectua mediante doce suplementos mensuales. Para facilitar la tarea de los parses exportadores, en esos doce suplementos figuran todos los totales de las previsiones y no s610 las cifras que se han modificado. De este modo, cada suplemento anula y sustituye por completo el cuadro publicado. Con el fin de acelerar la comunicaci6n de los suplementos alas autoridades nacionales competentes. los once primeros suplementos s610 aparecen en ingllls. La lectura de estos once suplementos en espai'lol y en frances se vera facilitada si se consultan los Indices de palses y territorios que figuran al final de la publicaci6n anual. El ultimo suplemento sera trilingiie. E/INCB/1989/2/Supp.10 31.10.1990 UNITED NATIONS PUBLICATION ISSN 1013-8250 00200P ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN 1990 TOTAL OF ESTIMATES TOTAL OF ESTIMATES IN GRAMS IN GRAMS AFGHANISTAN ANGOLA CANNABIS RESIN 1 CODEINE 7 620 COCAINE 1 DEXTROMO RAM I DE 1 CODEINE 299 700 FENTANYL 15 ETHYLMORPHINE 1 640 MORPHINE 30 FENTANYL 10 PETHIDINE 365 HEROIN 1 METHADONE 50 ANGU ILLA MORPHINE 500 OPIUM 8 000 COCAINE 2 PETHIDINE 4 675 CODEINE 3 DIHYDROCODEINE 11 ALBANIA FENTANYL 1 MORPHINE 3 COCAINE 1 837 PETHIDINE 54 CODEINE 53 931 ETHYLMORPHINE 2 112 ANTIGUA AND BARBUDA FENTANYL 10 OPIUM 184 000 COCAINE 20 PETHIDINE 6 264 CODEINE 500 FENTANYL 1 ALGERIA MORPHINE 10 PETHIDINE 375 ALFENTANIL 12 CODEINE 355 000 ARGENTINA DEXTROMORAMIDE 1 626 ETORPHINE 2 ALFENTANIL 140 FENTANYL 20 CANNABIS 5 MORPHINE 749 CANNABIS RESIN 10 PETHIDINE 11 815 COCA LEAF 5 PHENOPERIDINE 410 COCAINE 2 000 PHOLCODINE 620 000 CODEINE 436 857 CONC. OF POPPY STRAW 600 000 ANDORRA DEXTROPROPOXYPHENE 2192 000 DIHYDROCODEINE 120 000 COCAINE 20 DIPHENOXYLATE 6 001 CODEINE 25 ECGONINE 2 DEXTROMORAMIDE 5 ETHYLMORPHINE 60 318 ETHYLMORPHINE 5 ETORPHINE 1 FENTANYL 5 FENTANYL 243 METHADONE 20 HEROIN 1 MORPHINE 25 HYDROCODONE 62 031 OPIUM 5 METHADONE 1 PETHIDINE 200 MORPHINE 510 000 PHENOPERIDINE 13 OPIUM 15 269 TILlDINE 5 OXYCODONE 10 282 PAGE 2 TOTAL OF ESTIMATES IN GRAMS TOTAL OF ESTIMATES IN GRAMS ARGENTINA (continued) AUSTRALIA (continued) ------------------------- ------------------------- OXYMORPHONE 2 020 OXYCODONE 458 466 PETHIDINE 120 000 OXYMORPHONE 170 010 PHOLCODINE 62 267 PETHIDINE 844 624 SUFENTANIL 110 PETHIDINE INT.-A 620 000 THEBAINE 168 801 PETHIDINE INT.-B 10 PHENOPERIDINE 306 ARUBA PHOLCODINE 464 428 ------------------------- SUFENTANIL 10 BEZITRAMIDE 9 THEBAINE 1402 000 COCAINE 200 TILlDINE 10 000 CODEINE 750 TRIMEPERIDINE 10 DEXTROMORAMIDE 6 FENTANYL 1 HYDROCODONE 15 METHADONE 25 AUSTRIA MORPHINE 100 ------------------------- NICOMORPHINE 5 6-MONOACETYLMORPHINE 5 OPIUM 500 ALFENTANIL 110 OXYCODONE 4 COCAINE 2 362 PETHIDINE 1 150 CODEINE 224 960 CODEINE-6-GLUCURONIDE 1 ASCENSION ISLAND DEXTROPROPOXYPHENE 275 398 ------------------------- DIHYDROCODEINE 233 410 FENTANYL 1 ETHYLMORPHINE 2 804 MORPHINE 8 ETORPHINE 12 PETHIDINE 17 FENTANYL 338 METHADONE 48 915 AUSTRALIA METOPON 1 ------------------------- MORPHINE 91 140 ALFENTANIL 142 NICOCODINE 21 456 ANILERIDINE 150 000 * NICOMORPHINE 51 817 COCAINE 20 556 OPIUM 9 755 CODEINE 10291 000 PETHIDINE 176 430 CONC. OF POppy STRAW 57220 000 PHENAZOCINE 8 DEXTROMORAMIDE 12 648 PIRITRAMIDE 7 096 DEXTROPROPOXYPHENE 1389 000 SUFENTANIL 44 DIFENOXIN 10 THEBAINE 100 DIHYDROCODEINE 512 092 DIPHENOXYLATE 129 619 DIPIPANONE 10 ECGONINE 10 BAHAMAS ETHYLMORPHINE 40 736 ------------------------- ETONITAZENE 10 CANNABIS 35 ETORPHINE 10 COCAINE 300 FENTANYL 478 CODEINE 1 500 HYDROCODONE 29 813 DEXTROPROPOXYPHENE 6 000 HYDROMORPHONE 5 050 FENTANYL 1 LEVORPHANOL 10 HEROIN 1 METHADONE 216 247 HYDROCODONE 100 METHADONE-INTERMEDIATE 60 000 METHADONE 20 MORPHINE 16273 000 MORPHINE 200 MORPHINE DIMETHYLETHER 1 OPIUM 20 NORCODEINE 1 OXYCODONE 500 NORMETHADONE 19 842 PETHIDINE 10 000 OPIUM 5064 000 PHOLCODINE 300 PAGE 3 TOTAL OF ESTIMATES IN GRAMS TOTAL OF ESTIMATES IN GRAMS BAHRAIN BELGIUM (continued) ALPHAPRODINE 1 LEVORPHANOL 20 ANILERIDINE 1 METHADONE 12 599 COCAINE 89 MORPHINE 5005 000 CODEINE 559 NICOMORPHINE 20 DEXTROMORAMIDE 1 NORMETHADONE 36 737 FENTANYL 2 OPIUM 240 000 MORPHINE 64 OXYCODONE 6 045 PETHIDINE 4 464 PETHIDINE 48 032 PHENOPERIDINE 2 PETHIDINE INT.-B 82 PHENAZOCINE 20 BANGLADESH PHENOPERIDINE 40 000 * PHOLCODINE 336 039 CODEINE 10 000 PIRITRAMIDE 300 000 * FENTANYL 1 RACEMETHORPHAN 20 METHADONE 261 SUFENTANIL 69 MORPHINE 17 840 THEBACON 71 334 PETHIDINE 300 000 THEBAINE 139 490 PHOLCODINE 93 600 TILIDINE 1928 000 BARBADOS BELIZE COCAINE 100 COCAINE 25 CODEINE 15 000 CODEINE 2 600 DIHYDROCODEINE 1 530 DIHYDROCODEINE 150 FENTANYL 8 FENTANYL 10 METHADONE 15 MORPHINE 100 MORPHINE 289 PETHIDINE 5 000 OPIUM 3 250 PETHIDINE 5 000 BENIN BELGIUM DEXTROMORAMIDE 12 FENTANYL 2 ACETYLDIHYDROCODEINE 43 657 MORPHINE 15 ALFENTANIL 750 PETHIDINE 7 698 BEZITRAMIDE 4 672 CANNABIS 147 BERMUDA COCA LEAF 19 079 COCAINE 67 585 COCAINE 200 CODEINE 3076 000 CODEINE 2 000 CONC. OF POppy STRAW 3000 000 DEXTROMORAMIDE 15 DEXTROMORAMIDE 150 000 * DIHYDROCODEINE 1 000 DEXTROPROPOXYPHENE 217 095 ETORPHINE 5 DIETHYLTHIAMBUTENE 20 FENTANYL 1 DIFENOXIN 100 METHADONE 400 DIHYDROCODEINE 237 775 MORPHINE 1 000 DIPHENOXYLATE 299 474 * OPIUM 100 DIPIPANONE 60 OXYCODONE 100 ETHYLMORPHINE 276 013 PETHIDINE 3 000 ETORPHINE 20 ETOXERIDINE 20 BHUTAN HEROIN 22 488 HYDROCODONE 90 919 CODEINE 600 HYDROMORPHONE 327 DEXTROPROPOXYPHENE 325 ISOMETHADONE 20 MORPHINE 20 LEVOMO RAM I DE 16 PETHIDINE 250 PAGE 4 TOTAL OF ESTIMATES IN GRAMS TOTAL OF ESTIMATES IN GRAMS BOLIVIA BULGARIA ALFENTANIL 30 COCAINE 37 160 CODEINE 11 610 CODEINE 8033 000 DEXTROPROPOXYPHENE 100 000 DEXTROMORAMIDE 70 DIHYDROCODEINE 5 000 DEXTROPROPOXYPHENE 20 000 ETHYLMORPHINE 10 000 DIPHENOXYLATE 76 050 FENTANYL 8 ETHYLMORPHINE 403 374 HYDROCODONE 3 000 FENTANYL 154 METHADONE 2 000 METHADONE 70 PETHIDINE 3 000 MORPHINE 1352 000 OPIUM 2989 000 PETHIDINE 161 625 BOTSWANA PIRITRAMIDE 6 979 TILIDINE 88 579 CODEINE 300 TRIMEPERIDINE 600 DEXTROPROPOXYPHENE 1 250 DIHYDROCODEINE 600 BURKINA FASO DIPIPANONE 5 ETORPHINE 6 DEXTROMO RAM I DE 414 FENTANYL 2 FENTANYL 14 MORPHINE 30 MORPHINE 948 PETHIDINE 3 110 PETHIDINE 2 167 TILIDINE 60 PHENOPERIDINE 264 BURUNDI BRAZIL CODEINE 18 000 CODEINE 2900 000 DEXTROMORAMIDE 4 DEXTROPROPOXYPHENE 6500 000 FENTANYL 10 DIPHENOXYLATE 700 000 * HYDROCODONE 10 FENTANYL 1 500 MORPHINE 30 HYDROCODONE 250 NORMETHADONE 2 MORPHINE 2580 000 OPIUM 2 278 OPIUM 1020 000 OXYCODONE 1 PETHIDINE 600 000 PETHIDINE 1 250 CAMBODIA BRITISH VIRGIN ISLANDS COCAINE 8 000 CODEINE 50 000 CODEINE 600 ETHYLMORPHINE 1 000 DIHYDROCODEINE 150 MORPHINE 2 000 DIPHENOXYLATE 25 OPIUM 5 000 MORPHINE 4 PETHIDINE 1 000 PETHIDINE 345 PHOLCODINE 2 000 BRUNEI DARUSSALAM CAMEROON COCAINE 150 DEXTROMORAMIDE 106 CODEINE 2 600 FENTANYL 71 FENTANYL 1 MORPHINE 1 083 METHADONE 40 OPIUM 1 574 MORPHINE 24 PETHIDINE 18 415 OPIUM 450 PHENOPERIDINE 12 PETHIDIRE 1 500 PHOLCODINE 6 000 PAGE 5 TOTAL OF ESTIMATES IN GRAMS TOTAL OF ESTIMATES IN GRAMS CANADA CENTRAL AFRICAN REPUBLIC ALFENTANIL 606 CODEINE 6 000 ALPHAPRODINE 1 541 DEXTROMORAMIDE 4 ANILERIDINE 89 000 DEXTROPROPOXYPHENE 350 COCA LEAF 22 100 DIPHENOXYLATE 125 COCAINE 44 493 OPIUM 3 110 CODEINE 14428 000 PETHIDINE 140 DEXTROPROPOXYPHENE 1503 000 PHOLCODINE 700 DIFENOXIN 1 DIPHENOXYLATE 18 058 CHAD DIPIPANONE 9 ECGONINE 1 CODEINE 1 040 ETHYLMORPHINE 1 156 DEXTROMORAMIDE 20 ETORPHINE 3 FENTANYL 20 FENTANYL 673 MORPHINE 1 136 HEROIN 7 873 PETHIDINE 720 HYDROCODONE 114 873 PHENOPERIDINE 13 HYDROMORPHONE 39 545 LEVORPHANOL 3 236 METHADONE 37 592 CHILE MORPHINE 715 574 NORCODEINE 1 ALFENTANIL 150 NORMETHADONE 144 561 COCAINE 30 NORMORPHINE 1 CODEINE 359 564 OPIUM 85 790 DIPHENOXYLATE 685 OXYCODONE 124 507 ETHYLMORPHINE 15 000 OXYMORPHONE 340 FENTANYL 90 PETHIDINE 1021 000 METHADONE 2 000 SUFENTANIL 30 MORPHINE 4 787 OPIUM 150 PETHIDINE 32 229 SUFENTANIL 1 CAPE VERDE FENTANYL 1 CHINA METHADONE 19 MORPHINE 10 ALFENTANIL 10 PETHIDINE 671 COCAINE 5 500 CODEINE 716 334 ETHYLMORPHINE 10 000 ETORPHINE 1 FENTANYL 152 CAYMAN ISLANDS MORPHINE 289 505 OPIUM 18661 000 ALFENTANIL 2 PETHIDINE 2219 000 COCAINE 40 SUFENTANIL 2 CODEINE 1 500 CONC.
Load more

Recommended publications
  • Opioid Powders Page: 1 of 9
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 1 of 9 Last Review Date: March 13, 2020 Opioid Powders Description Buprenorphine Powder, Butorphanol Powder, Codeine Powder, Hydrocodone Powder, Hydromorphone Powder, Levorphanol Powder, Meperidine Powder, Methadone Powder, Morphine Powder, Oxycodone Powder, Oxymorphone Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, and oxymorphone powders are opioid drugs that are used for pain control. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death (1-15). Regulatory Status 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 2 of 9 FDA-approved indications: 1.
    [Show full text]
  • Epidural Ketamine for Postoperative Analgesia
    16 Mohamed Naguib M~ SCH MSC, Epidural ketamine Yaw Adu-Gyamfi MB, CHS FVARCS, FWACS, Gamil H. Absood PHO, for postoperative Hesham Farag ras scH FFARCS, Henry K. Gyasi MB CHa FFARCSl analgesia Thirty-four patients of ASA physical status 1 or H Following the identification of opiate receptors in scheduled for gall bladder surgery were studied in a the spinal cord, 1 the epidural and intrathecal use comparative prospective trial to evaluate the efficacy of of opioids has increased. However, these methods epidural and intramuscular ketamine for postoperative of pain relief are not without side-effects, 2 the most pain relief. They were divided randomly into three serious of which is delayed respiratory depression.3 groups. Group I (11 patients) received 30rag intra- Ketamine [2-(O-Chlorophenyl)-2-(methylamino) muscular ketamine. Group 11 (10 patients) and Group 111 cyclohexanone HCI] is a potent analgesic. 4 Recent (13 patients) received 10 and 30rag ketamine in 1Oral studies indicate that analgesia produced by ketamine saline respectively, through epidural catheters. Pain was is mediated by opiate receptors, s'6 Since ketamine evaluated every two hours for the first 24 hours post. administered systemically is unlikely to produce operatively by using a linear analogue pain scale from respiratory depression, 7 it seemed to offer an 0-10. Ketamine was given on the patient's request and obvious advantage over the opiates. whenever the pain score exceeded three. Ketamine pro- The demonstration of the safety of intrathecal duced analgesia in all patients studied. The reduction of ketamine with preservatives in baboons by Brock- pain score after two andJbur hours in Group I and lll was Utne et al.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products
    OPIOID IR COMBO DRUGS Apadaz* (benzhydrocodone-acetaminophen), Codeine-acetaminophen, Dvorah* (dihydrocodeine-caffeine-acetaminophen*), Hydrocodone-acetaminophen, Hydrocodone- acetaminophen solution 10-325mg*, Hydrocodone-ibuprofen, Nalocet* (oxycodone- acetaminophen*), Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Primlev*/Prolate* (oxycodone-acetaminophen*), Tramadol-acetaminophen, Trezix (dihydrocodeine-caffeine-acetaminophen) *Prior authorization for certain non-covered formulations applies only to formulary exceptions Pre - PA Allowance Age 12 years of age or older – Ultracet (tramadol and acetaminophen) and Codeine/APAP products Quantity Patients 18 years or older will be able to fill the Pre-PA Allowance after they have filled an initial 7 day supply of IR opioid therapy or if they have been on IR or ER opioid therapy in the last 180 days Patients age 17 and under will require a PA after they have filled a 3 day supply of the Pre- PA Allowance Patients with opioid addiction treatment or methadone in the last 30 days will not be eligible for Pre-PA Allowance Immediate Release Tablets or Capsules ≤ 50 MME/day Medication Strength Quantity Limit Codeine/APAP soln 120-12 mg/5 mL Hydrocodone/APAP soln 7.5/325 mg/15 mL 5400 mL per 90 days Hydrocodone/APAP elixir 10/300 mg/15 mL Oxycodone/APAP soln 5-325 mg/5 mL 3000 mL per 90 days Hydrocodone/ibuprofen 5/200 mg, 7.5/200 mg, 10/200 mg 270 units per 90 days Oxycodone/ibuprofen 5/400 mg Oxycodone/APAP 10/325 mg Codeine/APAP 60/300 mg Hydrocodone/APAP 7.5/300 mg, 7.5/325
    [Show full text]
  • Removing Samidorphan from Schedule II
    The Acting Administrator of the Drug Enforcement Administration issued an order to extend the temporary schedule I status of ethyl 2-(1-(5- fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: 5F-EDMB-PINACA); methyl 2-(1-(5-fluoropentyl)-1H-indole-3- carboxamido)-3,3-dimethylbutanoate (Other name: 5F-MDMB-PICA); N- (adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other names: FUB-AKB48, FUB-APINACA, AKB48, N-(4-fluorobenzyl)); 1-(5- fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole- 3-carboxamide (Others names: 5F-CUMYL-PINACA; SGT-25); and (1-(4- fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other name: FUB-144), and their optical, positional, and geometric isomers, salts, and salts of isomers. This order will extend the temporary scheduling of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL- PINACA and FUB-144 for one year or until the permanent scheduling action for these substances is completed, whichever occurs first. This order was published in the March 31, 2021 issue of the Federal Register, Volume 86, Number 60, pages 16669-16670 and was effective April 16, 2021. The Acting Administrator of the Drug Enforcement Administration issued a final rule removing samidorphan (3-carboxamido-4-hydroxy naltrexone) and its salts from the schedules of the Controlled Substances Act. This final rule was published in the April 19, 2021 issue of the Federal Register, Volume 86, Number 73, pages 20284-20286 and was effective April 19, 2021. This action was based upon the following: 1. Samidorphan does not possess abuse or dependence potential, 2.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • The International Drug Control Conventions
    ST/CND/1/Add.1/Rev.3 The International Drug Control Conventions Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as at 22 April 2017 UNITED NATIONS New York, 2017 ST/CND/1/Add.1/Rev.3 © United Nations, 2017. All rights reserved, worldwide. Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as at 22 April 2017 List of drugs included in Schedule I Acetorphine 3-O-Acetyltetrahydro-7α-(1-hydroxy-1-methylbutyl)- 6,14-endo-ethenooripavine Acetyl-alpha-methylfentanyl N-[1-(α-Methylphenethyl)-4-piperidyl]acetanilide Acetylfentanyl N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide Acetylmethadol 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane AH-7921 3,4-dichloro-N-{[1- (dimethylamino)cyclohexyl]methyl}benzamide Alfentanil N-[1-[2-(4-Ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl) ethyl]-4-(methoxymethyl)-4-piperidinyl]-N- phenylpropanamide Allylprodine 3-Allyl-1-methyl-4-phenyl-4-propionoxypiperidine Alphacetylmethadol α-3-Acetoxy-6-dimethylamino-4,4-diphenylheptane Alphameprodine α-3-Ethyl-1-methyl-4-phenyl-4-propionoxypiperidine Alphamethadol α-6-Dimethylamino-4,4-diphenyl-3-heptanol alpha-Methylfentanyl N-[1-(α-Methylphenethyl)-4-piperidyl]propionanilide alpha-Methylthiofentanyl N-[1-[1-Methyl-2-(2-thienyl)ethyl]-4-piperidyl] propionanilide Alphaprodine α-l,3-Dimethyl-4-phenyl-4-propionoxypiperidine Anileridine 1-p-Aminophenethyl-4-phenylpiperidine-4-carboxylic acid ethyl ester Benzethidine 1-(2-Benzyloxyethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • Effects of Medication-Assisted Treatment (MAT) on Functional Outcomes Among Patients with Opioid Use Disorder (OUD)
    NATIONAL DEFENSE RESEARCH INSTITUTE Effects of Medication- Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes A Systematic Review Margaret A. Maglione, Laura Raaen, Christine Chen, Gulrez Shah Azhar, Nima Shahidinia, Mimi Shen, Ervant J. Maksabedian Hernandez, Roberta M. Shanman, Susanne Hempel Prepared for the Office of the Secretary of Defense Approved for public release; distribution unlimited For more information on this publication, visit www.rand.org/t/RR2108 Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation R® is a registered trademark. Limited Print and Electronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions. The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. Support RAND Make a tax-deductible charitable contribution at www.rand.org/giving/contribute www.rand.org Preface Over the past two decades, the U.S. Department of Defense (DoD) has invested unparalleled resources into developing effective treatments for military-related psychological health conditions.
    [Show full text]
  • Opioid-Containing Cough and Cold Products - Assessing the Potential Risk of Opioid Use Disorder and Related Harms in Children and Adolescents
    Summary Safety Review –Opioid-containing cough and cold products - Assessing the potential risk of opioid use disorder and related harms in children and adolescents Product: Cough and cold products containing opioids (including codeine, hydrocodone or normethadone) Potential Safety Issue: Opioid use disorders and related harms in children and adolescents Key Messages • The growing number of overdoses and harms caused by opioids is a major public health concern in Canada. Cough and cold products containing opioids (including codeine, hydrocodone or normethadone) are authorized for sale in Canada to treat cough and cold symptoms in adults and children. • Health Canada reviewed the risk of opioid use disorder and related harms from these products after the United States Food and Drug Administration (US FDA) advised against using these products in children and adolescents in 2018. Health Canada’s safety review found limited evidence to link opioid-containing cough and cold products with opioid use disorders and related harms in children and adolescents. • These products are linked to other known harms (i.e., breathing problems), and there is limited evidence to support the effectiveness of these products in children and adolescents. There are other products available in Canada to help relieve the symptoms of cough and cold in children. • Therefore, Health Canada, as a precautionary measure, is advising Canadians against the use of these products among children and adolescents under 18 years of age. Health Canada will notify the manufacturers to update the product safety information of opioid- containing cough and cold products to limit the recommended age of use (indication) to adults only, 18 years of age and older.
    [Show full text]
  • List of Narcotic Drugs Under International Control
    International Narcotics Control Board Yellow List Annex to Forms A, B and C 59th edition, July 2020 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, r etaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. V.20-03697 (E) *2003697* Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in the form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention as well as intermediate opiate raw materials; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention.
    [Show full text]